Physicians serving as clinical investigators in Knoxville, Tennessee, working for Alliance for Multispecialty Research (AMR) and the University of Tennessee Medical Center, initiated a clinical trial targeting a vaccine for respiratory syncytial virus (RSV), a common, contagious virus triggering infections in the respiratory tract. A negative-sense, single-stranded RNA virus, RSV, represents the single most common cause of respiratory hospitalization in infants, while reinfection remains a problem later in life. This study is led by AMR’s founder, president, and principal investigator Dr. William Smith.
The Centers for Disease Control and Prevention (CDC) estimates that over 177,000 older adults are hospitalized annually with 14,000 deaths due to RSV. By 2018, AMR reports that more Americans died from RSV infection than the common flu.
The virus is most commonly found in children from newborn to four (4) years old. But this virus can manifest later in life, much like the flu or coronavirus, triggering long-term damage to the lungs, for example. The condition can lead to life-threatening situations.
In 2018, Pfizer reported that about 33 million cases of R...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).